FIELD: medicine; pharmaceuticals.
SUBSTANCE: invention relates to the pharmaceutical industry, in particular to a composition that prevents the abuse of a pharmaceutically active ingredient, including a pharmaceutically active ingredient, an acid soluble ingredient and a buffering agent (versions).
EFFECT: composition described above makes it possible to reduce abuse and minimise the possibility of developing physical or psychological dependence.
14 cl, 5 dwg, 1 tbl, 4 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COMPOSITIONS COMPRISING INHIBITORS OF DOPAMINE RE-UPTAKE AND METHODS FOR THEIR USING | 1999 |
|
RU2238084C2 |
| NEW CRYSTALLINE FORM OF 7-BROMO-1-(HYDRAZINOCARBONYL)METHYL-5-PHENYL-1,2-DIHYDRO-3H-1,4-BENZODIAZEPINE-2-ONE AND PHARMACEUTICAL APPLICATION THEREOF | 2021 |
|
RU2780646C1 |
| COMPOSITIONS CONTAINING MONOAMINE REUPTAKE INHIBITOR AND METHODS OF THEIR APPLICATION | 2004 |
|
RU2358719C2 |
| MEDICINAL FORM PROTECTED AGAINST NON-INTENDED USE | 2004 |
|
RU2354357C2 |
| SOLID MEDICINAL FORM ABLE TO CONSTANT RELEASE OF ACTIVE SUBSTANCE ALPRAZOLAM AND METHOD OF ITS PREPARING | 1994 |
|
RU2142791C1 |
| MEDICINAL COMPOSITION FOR RELEASE-CONTROL | 1994 |
|
RU2174832C2 |
| PROTEIN TYROSINE KINASE RECEPTOR INHIBITOR COMPOSITIONS | 2009 |
|
RU2586212C2 |
| TRICYCLIC BENZODIAZEPINES, PHARMACEUTICAL COMPOSITION CONTAINING THE SAME AND METHODS FOR HYPERTENSION TREATMENT | 1999 |
|
RU2250899C2 |
| PHARMACEUTICAL COMPOSITION | 2002 |
|
RU2323006C2 |
| PHARMACEUTICAL COMPOSITIONS OF METABOTROPIC GLUTAMATE RECEPTOR 5 (MGLU5) ANTAGONISTS | 2011 |
|
RU2602955C2 |
